Studying cancer in pet dogs to find new treatments for human patients

Oct 13, 2009

A team of scientists at the National Cancer Institute (NCI) in Bethesda, USA, says that studying pet dogs with cancer could yield valuable information on how to diagnose and treat human cancers. In this week's PLoS Medicine, the team discusses an ongoing initiative in which spontaneously occurring cancers in dogs are being studied to help inform the development of new cancer drugs, devices and imaging strategies for human cancer patients.

Estimates suggest that as many as 1 million new diagnoses of cancer occur in in the United States each year. The condition is treated much like human cancer, with surgery, radiation, and chemotherapy. owners are often motivated to pursue novel and investigational treatments with their veterinarians.

The team of scientists at the Centre for Cancer Research at the NCI, led by Dr. Chand Khanna, believes that studying these new therapies in clinical trials with dogs may yield insights into how to improve care for human patients. Naturally occurring tumors in dogs have clinical and biological similarities to the human disease.

Khanna and colleagues say that a pet owner's decision to pursue an experimental therapy is influenced by a number of factors, especially the possible risks and benefits of the new therapy and the reduced costs for care provided by the investigational trial.

Additionally, they say, "many pet owners are motivated by the opportunity to contribute to the advancement of cancer treatment for future human and canine patients."

The study of and treatment in animals with naturally occurring cancers, known as comparative oncology, is not a new concept. Over the last 30-40 years investigators have used this approach to advance understanding and treatment of several human cancers, such as (osteosarcoma), lymphoma, and melanoma.

More information: Gordon I, Paoloni M, Mazcko C, Khanna C (2009) The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Drug Development Pathway. PLoS Med 6(10): e1000161. doi:10.1371/journal.pmed.1000161

Source: Public Library of Science

Explore further: Phase 3 study may be game-changer for acute myeloid leukemia

add to favorites email to friend print save as pdf

Related Stories

Cancer cures could work for canines and humans

Jul 12, 2007

One of the major issues associated with longer life expectancy in man and his best friend is an increase in the incidence of cancer. Even though they cannot talk it seems dogs might be able to tell us why and how certain ...

Recommended for you

Phase 3 study may be game-changer for acute myeloid leukemia

2 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments : 0

More news stories

Sensors may keep hospitalized patients from falling

(Medical Xpress)—To keep hospitalized patients safer, University of Arizona researchers are working on new technology that involves a small, wearable sensor that measures a patient's activity, heart rate, ...

Fresh hope for preventing pneumonia in the elderly

There are calls for the frail and elderly not be be overlooked for vaccines against pneumonia this winter, with UNSW research challenging conventional wisdom on immunisation effectiveness in older patients.

Phase transiting to a new quantum universe

(Phys.org) —Recent insight and discovery of a new class of quantum transition opens the way for a whole new subfield of materials physics and quantum technologies.

Imaging turns a corner

(Phys.org) —Scientists have developed a new microscope which enables a dramatically improved view of biological cells.

NASA image: Volcanoes in Guatemala

This photo of volcanoes in Guatemala was taken from NASA's C-20A aircraft during a four-week Earth science radar imaging mission deployment over Central and South America. The conical volcano in the center ...